Basiliximab binds to the IL-2 T-lymphocyte receptor
Both
Neither
Basiliximab, bound to the IL-2 receptor on T-lymphocytes, prevents T-cell activation by the cytokine IL-2.
True
False
Basiliximab:
Marine-human chimeric monoclonal antibody (MAb).
In combination with cyclosporine and corticosteroids, basiliximab may be protective against acute organ rejection in individuals receiving kidney transplants.
Both
Neither
Basiliximab (Simulect):
Exhibits high affinity binding to the
α subunit of the IL-2 receptor.
Inhibits
both T-cell activation and proliferation
Both
Neither
Basiliximab:
Component of more general immunosuppressive protocols following organ transplantation.
Usually administered in a two-dose protocol: first administration 2 hours before surgery; second dosage 4 days after transplantation.
Both
Neither
Basiliximab:
Considered a relatively safe induction drug.
Cytokine release syndrome has not been described for basiliximab.
Both
Neither
Adverse effects/effects (toxicities/toxicity) associated with basiliximab administration:
Anaphylactic reactions
Lymphoproliferative disease (rare)
Opportunistic infections
A & B
B & C
A & C
A, B & C
Basiliximab combination treatment/treatments:
In combination with cyclosporine for microemulsion- and corticosteroid immunosuppression (panel reactive antibodies <80%)
Triple maintenance protocol for immunosuppression involving cyclosporine (microemulsion), corticosteroids along with either mycophenolate mofetil or azathioprine.
If you wish to return to the Table of Contents
in ENGLISH, press the RETURN button above.
Otherwise, if the text is NOT displayed in
English and you are ready to leave this page,
Press here
to return to the Table of Contents
Source Material:
Rothlin C Gutkind J Chapter 39
Immunosuppressants, Immunomodulation and Tolerance In
Goodman & Gilman's The Pharmacological Basis of Therapeutics
(Brunton LL Knollman BC eds) McGraw Hill LLC (2023).
Lake D & Briggs A Ch 55 Immunopharmacology
in Katzung's Basic & Clinical Pharmacology (Vanderah TW, ed)
16e McGraw Hill 2023.
Chrouos G Ch 39 Adrenocorticosteroids &
Adrenocortical Antagonists in Katzung's Basic & Clinical
Pharmacology (Vanderah TW, ed) 16e McGraw Hill 2023
Brezinski E Klickstein L Armstrong A Ch 46
Pharmacology of Immunosuppression in Principles of
Pharmacology: The Pathophysiologic Basis of Drug Therapy.
(Golan DE Armstrong EJ Armstrong AW, eds) 4e 2017 ls) 4e
2017
Ritter JM Flower R Henderson G Loke YK
MacEwan D Robinson E Fullerton J Ch 54 Anti-inflammatory and
Immunosuppressant Drugs Rang & Dale's Pharmacology 10e
Elsevier 2024.
Burchum J Rosenthal L Lehne's Pharmacology
for Nursing Care Ch 72 Immunosuppressants Elsevier 2022.
Burchum J Rosenthal L Lehne's Pharmacology
for Nursing Care Ch 75 Glucocorticoids in Nonendrocrine
Disorders Elsevier 2022.
Bass A Rogatsky Ch 32 Immunomodulatory Drugs
in Goldman-Cecil Medicine (Goldman L Schafer, eds) Elsevier
26e 2020
Leiva M Takemoto Ch 238 Immunosuppressants in
Lippincott Illustrated Reviews: Pharmacology 8e ((Walen et
al, eds) Wolters Kluwer 2023.
Hall J Hall M Ch 78 Adrenocortical
Hormones Guyton and Hall Textbook of Medical Physiology 14e
Elsevier 2021.
Waller DG Sampson A Hitchings Ch 38 A
Medical Pharmacology & Therapeutics 6e Elsevier 2022
